These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37968194)

  • 61. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
    Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
    Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
    Lee N; Lee JL; Lee JY
    Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
    Zhang Y; Zou JY; Wang Z; Wang Y
    Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
    Wang Z; Xu J; Nie W; Huang G; Tang J; Guan X
    Eur J Clin Pharmacol; 2014 Feb; 70(2):225-31. PubMed ID: 24150533
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meta-analysis of dermatological toxicities associated with sorafenib.
    Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
    Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of compound traditional Chinese medicine oil in alleviating regorafenib-induced hand-foot skin reaction.
    Zhang L; Cai J; Sun H; Shen L
    Asia Pac J Oncol Nurs; 2022 Feb; 9(2):125-129. PubMed ID: 35529418
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
    Chu D; Lacouture ME; Fillos T; Wu S
    Acta Oncol; 2008; 47(2):176-86. PubMed ID: 18210295
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
    Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
    J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bilateral sensorineural hearing loss induced by regorafenib.
    Cheng J; Wang L; Zhu LN; Wang L
    J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2022 Dec; 30(12):10203-10211. PubMed ID: 36217043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.